Thanks Ghia for the perspective on those Resolutions and Poly. And thanks Manifesto for the positivity.
Also I have been wondering if the time intervals between variants are getting shorter - how short can they get? -Also I don't know to what extent the possible mutations of the virus/spike are finite or infinite. But this can all turn up the pressure on the Covid situation.
Can you have a competition to see what goes up in this market? I had dinner with a friend last night who works on graphics and promotional material - he's currently working on a colossal skyscraper in NY that will be finished in 2030 and a city in Saudi Arabia that is going to be 'built in a long line' - his point was that money is moving, he is stuck in endless Zoom meetings in different time-zones and people are working and planning and building a future.
Even if there's no competition this month I would not be surprised to see SAR, Arizona Metals and PXEN go up this month. But...we shall see.
BTW...the scientists on Twitter, I find a few them by keeping an eye on Bloom Labs - various scientists are catalog-ing the next lot of variants. The thing is moving and shifting. Its not so much 'over' as finding new places from which to begin. So Covid is now creating a new post-Omicron family, as I understand it. And will be re-launching itself from that place. This is a long play.
Thank you very much Wigster and Doc83. You have done really well. That is first class work.
I hope Synairgen themselves have a good look at what you have produced. It is so much more informative and helpful than the colder style of the RNS or the Proactive interviews. If I'm right in thinking that many of the questions came from this board -then we have done really well as a team in terms of drawing out some very interesting information.
Synairgen remains a buy. Especially at this price point. Or anything under 40p IMO. But as Ghia noted, be patient.
Don't have the link but may dig it up over the next few days. Kind of super busy at the moment. But I was reading that BA5 may well be the beginning of the next set of lineages. There's no hurry here (for me).
Apologies if I posted this before but its a very interesting read - here are the details of the Pfizer/Valneva deal - I found it interesting because it gave me an example of how a bigger pharma will come in and work with a smaller pharma - its not a takeover - they call it a 'collaboration and license agreement'.
Its been potential multi bagger for a while - but the last RNS told us they actually have something valuable in the ground. And Michael Gentile in the picture - he has a great track record in picking miners....very pleased to buy some more today. Now sit back and wait.
I think someone was saying 'Oh I don't do social media...was there a rumour?'
I didn't find the rumour. But I did find this post from Tim Adams (he's a good source, a clear head) - its an interesting perspective....
"Noting the #SNG move since TR1 5 days ago. Pretty clear signal there's a plan at 27% holder Polygon/TFG. I believe that plan is in sync with @synairgen - not hostile. False start last month to 44p 16May. With AGM 30Jun we can expect indications of next steps soon... very soon."
I wonder. Poly not hostile. Poly engineer/broker a deal. Maybe something like Pfizer's deal with Valneva - Syn give away some equity and in return the pharma coming in give cash for trials and a timetable of milestone payments. And the closer we get to AGM, surely there might be some glimmer of light as to whether this is on the cards or not - I don't think people imagine Poly will sit around forever. I can see why its a time to buy. Get some good news a re a deal and this should rise nicely.
Could be re AGM. But....when we had the rise prior to the publication of the full year results (I think it was), that rise occurred just 24 hours before the results. We are a good week or so away from the AGM - it is possible this rise is something else. What are the theories? Traders doing something evil in the b/g or someone who can read the science/value is coming in.
Couldn't read the article - paywall and all that - but have wondered, casually if Synairgen might end up as a niche, high-cost drug - for a cohort of wealthy elderlies - but thats only an ill-informed guess.